We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

19 May 2026 - 22 May 2026
17 Jun 2026 - 19 Jun 2026
05 Oct 2026 - 06 Oct 2026

Preventing Unnecessary Radiotherapy for Patients with Early-Stage Hodgkin’s Lymphoma

By HospiMedica International staff writers
Posted on 27 Apr 2015
A new study suggested that patients with early-stage (stage 1a or 2a) Hodgkin’s lymphoma disease, who underwent three cycles of chemotherapy with the drugs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), and presented negative findings from Positron-Emission Tomography (PET), did not need additional field radiotherapy.

The study data was provided by a UK National Cancer Research Institute trial led by the University of Manchester (Manchester, UK) and the Christie NHS Foundation Trust, and published in the April 23, 2015, edition of the New England Journal of Medicine (NEJM).

The study included a total of 602 patients. More...
PET scanning revealed that the findings were negative in 426 patients. 209 of these patients received radiotherapy, and 211 patients received no further treatment. Patients in both groups were monitored for a period of 5 years.

The results of the study showed that patients with early-stage Hodgkin’s lymphoma who presented with negative PET findings, and had completed three cycles of chemotherapy had a very good prognosis either with or without consolidation radiotherapy. The survival rate of the group of 211 patients that received no further treatment was 90.8%.

Leader researcher of the study, Prof. John Radford, based at the University of Manchester, said, “This research is an important step forward. The results of RAPID show that in early stage Hodgkin lymphoma radiotherapy after initial chemotherapy marginally reduces the recurrence rate, but this is bought at the expense of exposing to radiation all patients with negative PET findings, most of whom are already cured.”

Related Links:

University of Manchester 



Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
New
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Glucose Meter
StatStrip®
New
Pediatric Mask
Respire SOFT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.